Human Anti-Tyrosinase Antibody Product Attributes
Species: Human
Tested Applications: Flow Cytometry, Immunofluorescence, Immunohistochemistry (IHC).
Application Notes: Flow Cytometry (0.5-1ug of antibody/million cells in 0.1ml), Immunofluorescence (1-2ug of antibody/ml), Immunohistochemistry (IHC) (Formalin-fixed) (0.5-1ug of antibody/ml for 30 minutes at RT)
Clonality: Monoclonal
Anti-Tyrosinase Antibody Clone: T311 + OCA1/812
Clone T311 + OCA1/812 Host and Isotype: Mouse IgG
Anti-Human Tyrosinase Positive Control Sample: SK-MEL-13, SK-MEL-19, SK-MEL-30, SK-MEL-37 cells or Melanoma.
Cellular Localization of Antibody Cytoplasmic
Buffer and Stabilizer: 10mM PBS with 0.05% BSA & 0.05% azide.
Antibody Concentration: 200ug/ml
Antibody Purification Method:Protein A/G Purified
Immunogen: Recombinant tyrosinase protein (T311); Recombinant human TYR protein (OCA1/812)
Storage Conditions: Store at 2 to 8° C (refrigerate). Stable for 24 months when properly stored.
Tyrosinase Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-TYR antibody staining is expected to be primarily localized to the vesicles.Observed Antibody Staining Data By Tissue Type:
Variations in Tyrosinase antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in melanocytes in skin. More moderate antibody staining intensity was present in melanocytes in skin. Low, but measureable presence of Tyrosinase could be seen in. We were unable to detect Tyrosinase in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of Tyrosinase expression as measured by anti-Tyrosinase antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal Intensity | - | - | - | - | - | - | - | - | - | - | +++ | - | - | - | - | - | - | - | - | - |
TYR Variability | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + |
Limitations and Warranty
enQuire Bio's Tyrosinase Anti-Human Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.